Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders
03/03/2026 14:07
March 3 (Reuters) - Pharmala Biotech Holdings Inc MDMA.CD: PHARMALA SIGNS SUPPLY & DATA AGREEMENT WITH NAUTILUS SANCTUARY FOR PHASE 2 MDMA CLINICAL TRIAL TREATING POST-TRAUMATIC STRESS AND ADJUSTMENT DISORDER IN FRONTLINE HEALTHCARE WORKERS AND FIRST RESPONDERS Source text: ID:nGNX8JgwBX Further company coverage: MDMA.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders